These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39020429)

  • 1. Human umbilical cord mesenchymal stem cell-based gene therapy for hemophilia B using scAAV-DJ/8-LP1-hFIXco transduction.
    Bu Z; Lou J; Xu W; Zhang L; Tang Y
    Stem Cell Res Ther; 2024 Jul; 15(1):210. PubMed ID: 39020429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
    Zhang R; Wang Q; Zhang L; Chen S
    Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates.
    Nathwani AC; Gray JT; McIntosh J; Ng CY; Zhou J; Spence Y; Cochrane M; Gray E; Tuddenham EG; Davidoff AM
    Blood; 2007 Feb; 109(4):1414-21. PubMed ID: 17090654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.
    Nathwani AC; Rosales C; McIntosh J; Rastegarlari G; Nathwani D; Raj D; Nawathe S; Waddington SN; Bronson R; Jackson S; Donahue RE; High KA; Mingozzi F; Ng CY; Zhou J; Spence Y; McCarville MB; Valentine M; Allay J; Coleman J; Sleep S; Gray JT; Nienhuis AW; Davidoff AM
    Mol Ther; 2011 May; 19(5):876-85. PubMed ID: 21245849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques.
    Mattar CN; Nathwani AC; Waddington SN; Dighe N; Kaeppel C; Nowrouzi A; Mcintosh J; Johana NB; Ogden B; Fisk NM; Davidoff AM; David A; Peebles D; Valentine MB; Appelt JU; von Kalle C; Schmidt M; Biswas A; Choolani M; Chan JK
    Mol Ther; 2011 Nov; 19(11):1950-60. PubMed ID: 21629224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained expression of coagulation factor IX by modified cord blood-derived mesenchymal stromal cells.
    Dodd M; Marquez-Curtis L; Janowska-Wieczorek A; Hortelano G
    J Gene Med; 2014; 16(5-6):131-42. PubMed ID: 24947827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
    Nathwani AC; Tuddenham EG; Rangarajan S; Rosales C; McIntosh J; Linch DC; Chowdary P; Riddell A; Pie AJ; Harrington C; O'Beirne J; Smith K; Pasi J; Glader B; Rustagi P; Ng CY; Kay MA; Zhou J; Spence Y; Morton CL; Allay J; Coleman J; Sleep S; Cunningham JM; Srivastava D; Basner-Tschakarjan E; Mingozzi F; High KA; Gray JT; Reiss UM; Nienhuis AW; Davidoff AM
    N Engl J Med; 2011 Dec; 365(25):2357-65. PubMed ID: 22149959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically modified adipose tissue-derived stem/stromal cells, using simian immunodeficiency virus-based lentiviral vectors, in the treatment of hemophilia B.
    Watanabe N; Ohashi K; Tatsumi K; Utoh R; Shim IK; Kanegae K; Kashiwakura Y; Ohmori T; Sakata Y; Inoue M; Hasegawa M; Okano T
    Hum Gene Ther; 2013 Mar; 24(3):283-94. PubMed ID: 23360488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose.
    Wu Z; Sun J; Zhang T; Yin C; Yin F; Van Dyke T; Samulski RJ; Monahan PE
    Mol Ther; 2008 Feb; 16(2):280-9. PubMed ID: 18059373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene therapy for hemophilia B mice with scAAV8-LP1-hFIX.
    Lu W; Zhou Q; Yang H; Wang H; Gu Y; Shen Q; Xue J; Dong X; Chen J
    Front Med; 2016 Jun; 10(2):212-8. PubMed ID: 27052253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial.
    Monahan PE; Sun J; Gui T; Hu G; Hannah WB; Wichlan DG; Wu Z; Grieger JC; Li C; Suwanmanee T; Stafford DW; Booth CJ; Samulski JJ; Kafri T; McPhee SW; Samulski RJ
    Hum Gene Ther; 2015 Feb; 26(2):69-81. PubMed ID: 25419787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B.
    Rogers GL; Martino AT; Zolotukhin I; Ertl HC; Herzog RW
    J Transl Med; 2014 Jan; 12():25. PubMed ID: 24460861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemophilia Gene Therapy: Ready for Prime Time?
    VandenDriessche T; Chuah MK
    Hum Gene Ther; 2017 Nov; 28(11):1013-1023. PubMed ID: 28793786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice.
    Chen Y; Schroeder JA; Kuether EL; Zhang G; Shi Q
    Mol Ther; 2014 Jan; 22(1):169-77. PubMed ID: 24042561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver.
    Nathwani AC; Gray JT; Ng CY; Zhou J; Spence Y; Waddington SN; Tuddenham EG; Kemball-Cook G; McIntosh J; Boon-Spijker M; Mertens K; Davidoff AM
    Blood; 2006 Apr; 107(7):2653-61. PubMed ID: 16322469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice.
    Zhang Y; Wang J; Ren M; Li M; Chen D; Chen J; Shi F; Wang X; Dou J
    J Ovarian Res; 2014 Jan; 7():8. PubMed ID: 24444073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B.
    Harding TC; Koprivnikar KE; Tu GH; Zayek N; Lew S; Subramanian A; Sivakumaran A; Frey D; Ho K; VanRoey MJ; Nichols TC; Bellinger DA; Yendluri S; Waugh J; McArthur J; Veres G; Donahue BA
    Gene Ther; 2004 Jan; 11(2):204-13. PubMed ID: 14712305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR/Cas9 technology.
    Ma Y; Sun W; Zhao L; Yao M; Wu C; Su P; Yang L; Wang G
    Stem Cell Res Ther; 2022 Jul; 13(1):353. PubMed ID: 35883203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lentiviral Gene Therapy for Bone Repair Using Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells.
    Bougioukli S; Saitta B; Sugiyama O; Tang AH; Elphingstone J; Evseenko D; Lieberman JR
    Hum Gene Ther; 2019 Jul; 30(7):906-917. PubMed ID: 30773946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
    Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
    Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.